

FORM 11

NOTICE OF PROPOSED GRANT OF STOCK OPTIONS AND RESTRICTED SHARE UNITS

Name of Listed Issuer: Cresco Labs Inc. (the "Issuer").

Trading Symbol: CL.CN

Date: May 06, 2026

1. New Grants:

Date of Grant: February 16th, 2026 and March 31st, 2026

Note: All Prices given are in Canadian Dollars.

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes, or No?	No. of Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Multiple	Employee	No	155,250	\$1.23	3/31/2036	155,250
Multiple	Employee	Yes	80,000	\$1.23	3/31/2036	80,000
Multiple	Employee	No	121,625 (Restricted Stock Units) ("RSUs")	N/A	N/A	167,875

Total number of shares proposed for acceptance: 356,875

2. Other Presently Outstanding Options and RSUs:

Position (Director/ Officer/ Employee/ Consultant/ Management Company)	No. of Shares ⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date
Board of Directors	2,510,894	\$2.38 - \$15.27	01/17/2019 - 03/15/2023	01/17/2029 - 03/15/2033
Key Management Personnel	9,403,050	\$1.06 - \$4.90	09/01/2018 - 01/02/2026	03/14/2028 - 01/02/2036
Employee	9,233,966	\$0.70 - \$15.88	11/16/2016 - 01/02/2026	11/16/2026 - 01/02/2036
Board of Directors	1,449,480	RSUs	06/30/2021 - 09/16/2025	N/A
Key Management Personnel	15,402,155	RSUs	01/03/2023 - 01/02/2026	N/A
Employee	11,868,764	RSUs	01/04/2022 - 01/02/2026	N/A

(1) Set out number of shares for each grant with different terms.

Total number of other presently outstanding options and RSUs: 49,868,309

Total number of shares outstanding: 50,225,184

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

November 14th, 2018 – Date of approval of incentive plan of Issuer.

July 10th, 2024 – Date of shareholder approval of an amended incentive plan.

- (b) State the date of the news release announcing the grant of options.

Not applicable

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

As of March 31st, 2026, the Issuer had 354,225,583 subordinate voting shares issued and outstanding.

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

0%

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

15,130,978 shares reserved for future grant as of the latest grant herein.

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

Not applicable

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

Please see Issuer's profile at www.sedarplus.ca for any publicly disclosed proposed material changes in the affairs of the issuer.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: May 06, 2026

John Schetz

Name of Director or Senior Officer

/s/ John Schetz

Signature

General Counsel

Official Capacity